Rhinitis, Allergic, Perennial Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis
The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
This study was a randomized, double-blind, placebo-controlled, phase III study with 2
parallel arms in adults and adolescents with HDM-associated allergic rhinitis (AR) for at
least one year.
The primary objective was to assess the efficacy of STG320 sublingual tablets at a daily
dosage of 300 IR when administered for 12 months to adults and adolescents with
HDM-associated AR. The primary efficacy variable was the average Total Combined Score.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01231464 -
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
Completed |
NCT00224523 -
Long Term Safety Of GW685698X Via Nasal Biopsy
|
Phase 3 | |
Completed |
NCT00658918 -
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
|
Phase 3 | |
Completed |
NCT00404586 -
Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber
|
Phase 1 | |
Withdrawn |
NCT02988778 -
Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00988247 -
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT01678807 -
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
|
Phase 1 | |
Completed |
NCT01644617 -
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
|
Phase 2 | |
Completed |
NCT01216384 -
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
|
Phase 1 | |
Completed |
NCT00848965 -
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
|
Phase 4 | |
Completed |
NCT00092118 -
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
|
Phase 3 | |
Completed |
NCT00839189 -
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
|
Phase 1 | |
Completed |
NCT00570492 -
Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
|
Phase 4 | |
Completed |
NCT00806754 -
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
|
Phase 4 | |
Recruiting |
NCT00153595 -
EWO1 in Persistent Allergic Rhinitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00132925 -
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT02498509 -
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
|
Phase 3 | |
Completed |
NCT01134705 -
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
|
Phase 3 | |
Completed |
NCT02238236 -
Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus
|
N/A |